Diazoxide

Articles · Medicine Compliance Aid Stability · Lactation Safety Information · New Medicines ·
58905004

Articles

Medicine Compliance Aid Stability

Eudemine · PharSafer

PharSafer
Eudemine
Tablets 50mg
A2 · Amber 2 · No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
No special precautions for storage
No special precautions for storage
27th January 2015

Lactation Safety Information

for hypoglycaemia

for hypoglycaemia
Long half-life increases risk of accumulation in breastfed infants
No published evidence of safety
Used in full-term neonates from birth
Monitor infant for hyperglycaemia
24th September 2020

for hypertension

for hypertension
Labetalol, Hydralazine
No published evidence of safety
Long half-life increases risk of accumulation in breastfed infants, although this risk is minimal with short-term emergency use
Monitor infant for hyperglycaemia
Used in full-term neonates from birth
24th September 2020

New Medicines

Obesity associated with Prader-Willi Syndrome (PWS) in adults and children - first-line. Controlled-release tablet.

Information

New formulation
Soleno Therapeutics
Soleno Therapeutics

Development and Regulatory status

Phase III Clinical Trials
None
Phase III Clinical Trials
Yes
Yes

Category

Diazoxide choline is an agonist of the KATP channel. The choline salt improves the solubility of diazoxide in aqueous solutions, contributing to improved bioavailability.
Prader-Willi syndrome (PWS) is the most commonly known genetic cause of life-threatening obesity and is a complex disorder that presents with a range of mental and physical findings. PWS occurs in approximately one out of every 15,000 births in England [1].
Obesity associated with Prader-Willi Syndrome (PWS) in adults and children - first-line. Controlled-release tablet.
Oral